Pancreatic Cancer Research

ResearcherSoongsil UniversityActive in the last 2 years

Jung Yong Hong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1363-9332; OpenAlex author ID A5013311116, A5159706235. Sources: OpenAlex.

Their work

Papers
15 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 6 papers

Papers 15

  1. Prediabetes Remission and the Subsequent Risk of Pancreatic Cancer: A Nationwide Cohort Study. First author DOI 10.1016/j.amepre.2025.107979↗
  2. Increased risk of young-onset pancreatic cancer among adults aged 20-39 years with overweight or obesity, but not underweight: A nationwide cohort study. Co-author DOI 10.1016/j.ejca.2025.116111↗
  3. Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study. First author DOI 10.1016/j.mayocp.2026.05.020↗
  4. Efficacy of neoadjuvant FOLFIRINOX in resectable pancreatic cancer (NeoFOL-R): study protocol for an international, multicenter, prospective, randomized contro… Co-author DOI 10.1186/s12885-026-15639-6↗
  5. Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age… First author DOI 10.1200/jco-25-01169↗
  6. Reply to: "Beyond Average Grams: Aldehyde Dehydrogenase 2*2 and Alcohol-Induced Young-Onset Pancreatic Cancer" and "Uncontrolled Prediabetes Confounding in the… First author DOI 10.1200/jco-26-01147↗
  7. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  8. L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. Co-author DOI 10.1038/s41598-025-07668-1↗
  9. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.ctro.2024.100732↗
  10. Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study. First author DOI 10.6004/jnccn.2023.7060↗
  11. Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study. Co-author DOI 10.1016/j.ejca.2021.12.027↗
  12. Increased risk of pancreatic cancer in individuals with non-alcoholic fatty liver disease. First author DOI 10.1038/s41598-022-14856-w↗
  13. Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. Co-author DOI 10.1053/j.gastro.2021.09.070↗
  14. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Co-author DOI 10.1177/17588359211038478↗
  15. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-013-2328-1↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joo‐Hyun Park · 8 shared papers, 2022–2026 · strength 2.28
  2. Kyungdo Han · 7 shared papers, 2022–2026 · strength 2.13
  3. Joon Oh Park · 10 shared papers, 2014–2026 · strength 2.07
  4. Young Suk Park · 8 shared papers, 2014–2026 · strength 1.87
  5. Ho Yeong Lim · 4 shared papers, 2014–2026 · strength 1.02
  6. In Woong Han · 4 shared papers, 2021–2026 · strength 0.71
  7. Joo Kyung Park · 3 shared papers, 2022–2025 · strength 0.58
  8. Jin Seok Heo · 3 shared papers, 2021–2025 · strength 0.52
  9. Sang Hyun Shin · 3 shared papers, 2021–2025 · strength 0.52
  10. Seung Tae Kim · 2 shared papers, 2021–2025 · strength 0.40
  11. Jong Kyun Lee · 2 shared papers, 2024–2025 · strength 0.38
  12. Kangpyo Kim · 2 shared papers, 2024–2025 · strength 0.38
  13. Ji Hye Min · 2 shared papers, 2024–2025 · strength 0.38
  14. Hee Chul Park · 2 shared papers, 2024–2025 · strength 0.38
  15. Kyu Taek Lee · 2 shared papers, 2024–2025 · strength 0.38
  16. Jeong Il Yu · 2 shared papers, 2024–2025 · strength 0.38
  17. Ho Yeong Lim · 1 shared paper, 2026 · strength 0.36
  18. J Y Park · 1 shared paper, 2026 · strength 0.36
  19. Hyun‐Jin Kim · 1 shared paper, 2026 · strength 0.33
  20. Hye-Lim Jang · 1 shared paper, 2025 · strength 0.27
  21. Kee‐Taek Jang · 1 shared paper, 2025 · strength 0.27
  22. Sook‐Young Woo · 1 shared paper, 2025 · strength 0.20
  23. Hongbeom Kim · 1 shared paper, 2025 · strength 0.20
  24. Jin Ho Choi MD · 1 shared paper, 2025 · strength 0.20
  25. Julian Choi · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.